A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Clinical trial NCT03150589 · COMPLETED
Trial details
- NCT number
- NCT03150589
- Sponsor
- Samsung Bioepis Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-14
- Primary completion
- 2019-05-24
- Enrollment
- 705
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.